Skip to content
Search AI Powered

Latest Stories

Military Invests in MDMA for PTSD Treatment

In a historic shift, the Department of Defense is funding two major clinical trials—totaling $9.8 million—to study the use of MDMA-assisted therapy for treating PTSD in active-duty service members. The research marks the first sanctioned exploration of psychedelics within the military. While the move signals progress, broader access to alternative therapies like cannabis and psilocybin remains blocked—leaving many veterans still fighting for healing options the government won’t yet fund.

the pentagon, washington dc, aerial view

The Pentagon Is Betting Nearly $10 Million on MDMA to Treat PTSD in Active-Duty Soldiers

The U.S. Department of Defense (DoD) has earmarked $9.8 million for pioneering research into the therapeutic potential of psychedelics, specifically MDMA, for active-duty service members grappling with post-traumatic stress disorder (PTSD). This initiative underscores a significant shift in military mental health strategies, acknowledging the pressing need for innovative treatments amid rising concerns over service members' well-being.Latest news & breaking headlines+1Military Times+1

Breaking Down the Investment


The funding is divided into two equal grants of $4.9 million:Military Times

  • Walter Reed National Military Medical Center: Set to conduct a double-blind, placebo-controlled trial, this study will administer MDMA to active-duty Army personnel diagnosed with mild to moderate PTSD. The primary objective is to assess how MDMA influences psychological flexibility, a key factor in effective PTSD treatment. Leading this research is Major Aaron Wolfgang, head of Inpatient Psychiatry at Walter Reed, who has previously contributed to comprehensive reviews on MDMA-assisted therapy. Military Times+1Latest news & breaking headlines+1
  • Emory University and STRONG STAR Consortium: Collaborating with the University of Texas Health Science Center at San Antonio, this partnership will explore MDMA-assisted therapy's efficacy in treating PTSD among active-duty troops. STRONG STAR is renowned for its focus on combat-related PTSD research, making it a pivotal player in this groundbreaking study.

A Historical Perspective

This endeavor marks the first sanctioned investigation into MDMA's therapeutic applications for PTSD within active-duty military personnel. Historically, the U.S. government's engagement with psychedelics in military contexts has been controversial, often associated with unauthorized experiments during the mid-20th century. This contemporary research signifies a departure from past practices, emphasizing scientific rigor and ethical standards.

The Broader Context: Veterans and Alternative Therapies

While the DoD's commitment to exploring psychedelics is a progressive step, it occurs against a backdrop of governmental resistance to alternative treatments for veterans. Efforts to expand access to cannabis and psychedelics for medical purposes have faced legislative hurdles. For instance, amendments proposing research into psilocybin and MDMA for PTSD and traumatic brain injury were recently rejected, leaving many veterans without access to potentially life-changing therapies.

FDA Approves Landmark Cannabis for PTSD in Veterans - The BluntnessFDA Approves Landmark Cannabis for PTSD in Veterans - The Bluntness Photo by Wesley Tingey on Unsplash

The Imperative for Innovative Solutions

The urgency for effective mental health interventions in the military community cannot be overstated. Studies have shown that women veterans are 1.8 times more likely than their civilian counterparts to commit suicide, highlighting the critical need for comprehensive and effective treatment options.

The DoD's $9.8 million investment in psychedelic research represents a hopeful development in addressing the complex mental health challenges faced by service members. As these studies progress, they hold the potential to reshape treatment paradigms and offer new avenues for healing to those who have served.

More For You

gif of actor Kevin James from King of Queens; asking "How Much Does That Cost?"
Why Is Some Weed More Expensive Than Others? Understanding Cannabis Pricing
Giphy

Unraveling Cannabis Pricing: Factors Behind the Cost of Weed


Step inside a cannabis dispensary for the first time and the experience can be overwhelming. The meticulously labeled glass jars showcase dozens of strains with names like "Wedding Cake" and "Blue Dream," while refrigerated cases display concentrates, edibles, and tinctures at wildly different price points. Unlike the days when consumers were limited to whatever their neighborhood dealer offered, today's legal market presents a dazzling array of options that might leave newcomers with both wonder and sticker shock.

Keep ReadingShow less
Comprehensive Glossary of Cannabis Terminology - The Bluntness
Cannabis Terminology - The Bluntness
Photo by Margo Amala on Unsplash

Are You Ready to Master Cannabis Lingo? Explore Essential Terms Now

This glossary covers key cannabis-related terms that can help consumers better understand the cannabis industry, products, and their effects. Whether you're new to cannabis or looking to deepen your knowledge, these definitions offer clarity on common terms you might encounter.

Cannabis Basics: What is Cannabis?

Cannabis is a fascinating plant species that includes three main types: Cannabis sativa, Cannabis indica, and Cannabis ruderalis. Each of these species has unique characteristics and effects. The cannabis plant is a complex organism, rich in various compounds such as cannabinoids, terpenes, and flavonoids. These compounds contribute to the plant’s diverse range of effects and therapeutic benefits. Cannabis plants are cultivated for both medicinal and recreational purposes, and they can be consumed in multiple forms, including dried flower, extracts, and edibles. Whether you’re interested in the energizing effects of Cannabis sativa, the relaxing properties of Cannabis indica, or the unique traits of Cannabis ruderalis, there’s a cannabis plant to suit every need.

Cannabis Products: Cannabis Extracts

Cannabis extracts are highly potent products derived from the cannabis plant using various extraction methods, such as solvents or CO2. These extracts are concentrated forms of cannabis that can be used in several ways, including dabbing, vaporizing, or as ingredients in edibles and topicals. There are several types of cannabis extracts, each with its own texture and potency, including wax, shatter, oil, and crumble. These products are often favored for their high cannabinoid content and are commonly used for medicinal purposes, such as pain relief and anxiety management. Whether you’re looking for a powerful dabbing experience or a potent ingredient for your homemade edibles, cannabis extracts offer a versatile and effective option.

Keep ReadingShow less
retail shelves stocked with legal cannabis products
The mix of in-state and out of state brands at a legal NY dispensary
The mix of in-state and out of state brands at a legal NY dispensary

NY's Pot Industry: Wins, Woes, Next

Two years into New York's adult-use cannabis rollout, the state's Office of Cannabis Management (OCM) has dropped its most comprehensive look yet at the market's performance, challenges, and opportunities. The 2024 OCM Market Report is packed with impressive numbers and lofty intentions, but peel back the layers and a more complicated story unfolds—one where equity goals face harsh economic headwinds, regulatory delays hamper progress, and a persistent illicit market looms large.

Here's what you need to know:

Keep ReadingShow less
map of medical and recreational cannabis retailers in state of New York
NY Cannabis Program Under Fire for Misconduct
NY Cannabis Program Under Fire for Misconduct

Legal Weed, Legit?

New York’s legal cannabis industry was supposed to be the nation’s model of equity and regulation. Instead, it’s quickly becoming a cautionary tale. And the latest news doesn’t just raise eyebrows—it should set off alarms across the entire industry.

According to an April 7 report by The New York Times, New York State regulators are conducting a sweeping investigation into some of the biggest cannabis companies operating in the state—Stiiizy, Grön, Mfused, and others—over allegations of using out-of-state or unauthorized cannabis to produce products for legal dispensaries. It’s a practice insiders call inversion—and it’s been the industry’s not-so-secret open secret for years.

Keep ReadingShow less
U.S. States with highest revenue from cannabis taxes
U.S. States with highest revenue from cannabis taxes

U.S. States with the Highest Revenue from Cannabis Taxes

The Drug Enforcement Agency (DEA) hasn't seen any reason to remove cannabis from its list of Schedule I banned substances. Yet, cannabis in its myriad forms is pulling in billions of dollars in vital tax revenue for those states where it is legal —$3 billion in 2022 alone.

The drug has sat in the Schedule I classification alongside heroin, peyote, and other substances the DEA considers to have a high potential for abuse since 1970, when Congress enacted the Controlled Substances Act, making it federally illegal to possess them. Two decades after the law passed, following intense social pressure that segued into the realization of a new tax opportunity, certain states began to make the drug available to residents, citing the medical benefits and relative safety compared with other substances

Keep ReadingShow less